Absence of miR-182 augments cardiac allograft survival

Transplantation

Volumn 101, Issue 3, 2017, Pages 524-530

  Wei, Liang ^a   Kaul, Vandana ^a   Qu, Xiumei ^a   Xiong, Xiaoxing ^a   Lau, Audrey H ^a   Iwai, Naoharu ^b   Martinez, Olivia M ^a   Krams, Sheri M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD4 ANTIGEN; HERMES ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA 182; TRANSCRIPTION FACTOR FKHR; ALLOANTIGEN; FOXO1 PROTEIN, MOUSE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MICRORNA; MIRN182 MICRORNA, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; WESTERN BLOTTING; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARDIAC MUSCLE; CELL CULTURE; DRUG EFFECTS; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; TIME FACTOR;

ABATACEPT; ALLOGRAFTS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; FORKHEAD BOX PROTEIN O1; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MYOCARDIUM; TIME FACTORS;

EID: 84997611148     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001345     Document Type: Article

References (37)

1. Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455:64-71.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
4. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92-105.
5. Duong Van Huyen JP, Tible M, Gay A, et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J. 2014;35:3194-3202.
6. Kaul V, Krams S. MicroRNAs as master regulators of immune responses in transplant recipients. Curr Opin Organ Transplant. 2015; 20:29-36.
7. Lu LF, Gasteiger G, Yu IS, et al. A single miRNA-mRNA interaction affects the immune response in a context-and cell-type-specific manner. Immunity. 2015;43:52-64.
8. Wei L, Wang M, Qu X, et al. Differential expression of microRNAs during allograft rejection. Am J Transplant. 2012;12:1113-1123.
9. Dong G, Wang Y, Xiao W, et al. FOXO1 regulates dendritic cell activity through ICAM-1 and CCR7. J Immunol. 2015;194:3745-3755.
10. Hsu P, Santner-Nanan B, Hu M, et al. IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J Immunol. 2015; 195:3665-3674.
11. Kerdiles YM, Stone EL, Beisner DR, et al. Foxo transcription factors control regulatory T cell development and function. Immunity. 2010;33: 890-904.
12. Peng SL. Foxo in the immune system. Oncogene. 2008;27:2337-2344.
13. Stittrich AB, Haftmann C, Sgouroudis E, et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol. 2010;11:1057-1062.
14. Wilflingseder J, Regele H, Perco P, et al. miRNA profiling discriminates types of rejection and injury in human renal allografts. Transplantation. 2013;95:835-841.
15. Bedi B, Li JY, Grassi F, et al. Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss. Ann N Y Acad Sci. 2010; 1192:215-221.
16. Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol. 2014;10:14-24.
17. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res. 2008;103:1220-1231.
18. Podojil JR, Turley DM, Miller SD. Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease. Adv Exp Med Biol. 2008;640:234-251.
19. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-1123.
20. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
21. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013;12: 130-146.
22. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl JMed. 2013;369:2416-2423.
23. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21: 1587-1596.
24. Jin ZB, Hirokawa G, Gui L, et al. Targeted deletion of miR-182, an abundant retinal microRNA. Mol Vis. 2009;15:523-533.
25. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation. 1973;16:343-350.
26. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant. 2011;11:1599-1609.
27. Pieper J, Herrath J, Raghavan S, et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.
28. Snanoudj R, Frangie C, Deroure B, et al. The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept. Biologics. 2007;1:203-213.
29. Wilflingseder J, Sunzenauer J, Toronyi E, et al. Molecular pathogenesis of post-transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles. PLoS One. 2014;9:e104164.
30. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284: 23204-23216.
31. Stahl M, Dijkers PF, Kops GJ, et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol. 2002;168:5024-5031.
32. Tejera MM, Kim EH, Sullivan JA, et al. FoxO1 controls effector-to-memory transition and maintenance of functional CD8 T cell memory. J Immunol. 2013;191:187-199.
33. Luo CT, Liao W, Dadi S, et al. Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity. Nature. 2016; 529:532-536.
34. Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology. 2013; 57:533-542.
35. Kelada S, Sethupathy P, Okoye IS, et al. miR-182 and miR-10a are key regulators of Treg specialisation and stability during Schistosome and Leishmania-associated inflammation. PLoS Pathogens. 2013;9:e1003451.
36. Pucella JN, Yen WF, Kim MV, et al. miR-182 is largely dispensable for adaptive immunity: lack of correlation between expression and function. J Immunol. 2015;194:2635-2642.
37. Li YF, Ou X, Xu S, et al. Loss of miR-182 affects B-cell extrafollicular antibody response. Immunology. 2016;148:140-149.